Streptokinase–plasminogen activation complex (SK-Pg complex)

The Streptokinase–plasminogen activation complex is a potent fibrinolytic assembly formed by the interaction of the bacterial protein streptokinase with human plasminogen (StatPearls, 2023). Unlike direct plasminogen activators like tissue plasminogen activator (tPA), streptokinase lacks intrinsic enzymatic activity and must form a 1:1 stoichiometric complex with plasminogen to induce a conformational change that exposes an active site without peptide bond cleavage (PubChem, 2024). This complex then functions as a serine protease, efficiently converting free plasminogen into plasmin, the primary enzyme responsible for degrading fibrin clots in the vasculature (NIH, 2022). Clinically, this complex is central to the pharmacological action of streptokinase and its derivatives in treating acute thromboembolic conditions such as myocardial infarction and pulmonary embolism. However, its use is limited by its systemic effect on fibrinogen and its high immunogenicity, as streptokinase is a foreign bacterial protein that can trigger allergic reactions or be neutralized by pre-existing antibodies (Wikipedia, 2024). The complex can also be administered in a pre-formed, acylated state known as anistreplase, which allows for bolus injection and improved clot targeting. Monitoring of the complex's activity is typically performed through markers of fibrinolysis such as D-dimer and fibrinogen depletion. Despite the advent of more fibrin-specific agents, the streptokinase-plasminogen complex remains a cost-effective option for thrombolysis in many clinical settings globally.

Other names

Streptokinase-plasminogen complexSK-plasminogen activator complexSK-PgStreptokinase-plasmin complexAnisoylated plasminogen streptokinase activator complex

Streptokinase binds to plasminogen to form a 1:1 stoichiometric complex that undergoes a conformational change, exposing an active site on plasminogen. This complex then acts as an enzyme to catalytically convert additional free plasminogen molecules into active plasmin, which degrades fibrin clots.